

2 October 2026

ASX Announcement

Galidesivir GMP manufacturing commences to support Ebola treatment and pivotal Marburg programs

- GMP manufacture of Galidesivir active pharmaceutical ingredient ("API") commenced on 1 October at PI Health Sciences ("PIHS")
- First 5kg GMP API batch targeted for completion by the end of October and earmarked for Island's approved emergency-use program in Uganda during the current Bundibugyo Ebola outbreak
- Galidesivir has been authorised for investigational therapeutic use under the WHO Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) framework
- Prospective clinical, safety and virological data to be collected from treated patients in the current Bundibugyo Ebola outbreak in Africa
- Current outbreak has resulted in 8,137 confirmed cases and 3,926 confirmed deaths, representing a confirmed case fatality ratio of approximately 48%
- Second 5kg GMP API batch targeted for completion by late November 2026
- Second batch to support Island's broader Ebola strategy and planned pivotal Marburg NHP study under the FDA Animal Rule
- Manufacturing program strengthens Galidesivir deployment readiness and establishes GMP supply to support human Ebola data generation, Marburg development and potential future government procurement and biodefence opportunities

MELBOURNE Australia, 2 October 2026: Australian antiviral drug development and biodefence company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) is pleased to advise that GMP manufacture of Galidesivir active pharmaceutical ingredient ("API") commenced on 1 October at PI Health Sciences ("PIHS"), marking the transition of the Company's expanded manufacturing program into physical production.

The multi-step manufacturing process is now underway, with the first 5kg batch of GMP-grade Galidesivir API targeted for completion by the end of October 2026. This first batch has been earmarked to support Island's approved emergency-use program during the ongoing Bundibugyo Ebola outbreak.

Following completion of API manufacture, Island will undertake the required finishing, vialing and packaging activities ahead of planned shipment to Uganda. For investigational therapeutic use under the World Health Organization's MEURI framework.

A second 5kg GMP API batch is targeted for completion by the end of November 2026. This additional supply is intended to support Island's broader Ebola strategy and material for the Company's planned pivotal Marburg non-human primate ("NHP") study under the US Food and Drug Administration's ("FDA") Animal Rule pathway.



Manufacturing is being undertaken at PIHS under the Company's existing agreement (refer ASX announcement: 4 June 2026). The broader program also encompasses analytical method validation, reference standard preparation and stability studies, establishing the manufacturing and quality framework required to support Galidesivir's continued development, potential outbreak deployment and future regulatory and government procurement activities.

The ongoing Ebola outbreak caused by Bundibugyo virus continues to represent a significant public health challenge. According to the latest available World Health Organization ("WHO") data, as at 27 September 2026, the outbreak had resulted in 8,137 confirmed cases and 3,926 confirmed deaths, representing a confirmed case fatality ratio of approximately 48%. The absence of an approved specific treatment for Bundibugyo Ebola virus disease underscores the need for additional medical countermeasures.

Galidesivir enters this program with an extensive existing development foundation. The broad-spectrum antiviral has benefited from more than US\$70 million of prior US Government investment and has existing human clinical experience together with historical efficacy data in NHP models of Ebola and Marburg virus disease. Island is now seeking to build on that foundation through two complementary evidence-generation pathways; prospective human data collection in Ebola under MEURI and controlled Marburg NHP studies supporting the FDA Animal Rule pathway.

Management commentary:

CEO and Managing Director, Dr David Foster said: *"The commencement of physical GMP manufacture is an important execution milestone for Galidesivir. The first 5kg campaign is now underway and our immediate objective is to establish GMP supply that can support the approved MEURI program while the Bundibugyo Ebola outbreak remains active.*

"Importantly, treatment under the MEURI framework will occur under a prospective protocol, creating the opportunity to collect clinical, safety and virological data from patients treated with Galidesivir. This has the potential to add an important human evidence stream to the substantial body of preclinical and clinical data already established for the drug.

"In parallel, the second 5kg manufacturing campaign is intended to support our broader Ebola strategy and planned pivotal Marburg NHP study. These are complementary development pathways intended to advance Galidesivir, pursuing potential real-world treatment experience in Ebola while progressing the defined Animal Rule pathway in Marburg.

"Together, these activities strengthen Galidesivir's development readiness as we work to position it as a potential broad-spectrum medical countermeasure for high-consequence viral threats."

- Ends -

Approved for release to the ASX by:

The Board of Island Pharmaceuticals Limited

info@islandpharmaceuticals.com



Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.